Lupus & antiphospholipid syndrome
Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis
Authors' conclusion
However, IF, rather than II or TA, was found to increase the risk of ESKD in our cohort.
Study context
- Population
- Patients with biopsy-proven LN (mean age 36 years; 90.1% female)biopsy-proven LN
- Participants
- 151 patients
- Exposure
- Tubulointerstitial lesion scores as risk factors for end-stage kidney disease (ESKD)
- Outcome
- ESKD
Methodological detailsbiopsy-proven LN, multivariate analysis, Kaplan-Meier analysis
- Biopsy-proven LN
- Multivariate analysis
- Kaplan-Meier analysis
Main finding
As reported in the abstract
Independent risk factors of ESKD (multivariate) · mean follow-up 58 months
Interstitial fibrosis (IF), HR (95% CI 1.58-6.49), P = 0.001
3.2
Serum creatinine, HR (95% CI 1.42-2.03), P < 0.001
1.7
Progressed to ESKD during follow-up
47
31.1%
Observational data: associations, not effects.
Further findings
- Patients with tubulointerstitial lesions
- 120 (79.5%)
- ESKD before renal biopsy
- nine (6.0%)
Original publication
Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis. Rheumatology (Oxford). Published 2 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →